EP2195036A4 - COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE - Google Patents

COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE

Info

Publication number
EP2195036A4
EP2195036A4 EP08725637A EP08725637A EP2195036A4 EP 2195036 A4 EP2195036 A4 EP 2195036A4 EP 08725637 A EP08725637 A EP 08725637A EP 08725637 A EP08725637 A EP 08725637A EP 2195036 A4 EP2195036 A4 EP 2195036A4
Authority
EP
European Patent Office
Prior art keywords
radioisotope
tumors
compositions
treatment
direct administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08725637A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2195036A1 (en
Inventor
R Keith Frank
Kenneth Mcmillan
Jaime Simon
H Max Loy
Stanley D Stearns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GABRIEL INSTITUTE, INC.
ISOTHERAPEAUTICS GROUP LLC.
Original Assignee
Gabriel Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gabriel Institute Inc filed Critical Gabriel Institute Inc
Publication of EP2195036A1 publication Critical patent/EP2195036A1/en
Publication of EP2195036A4 publication Critical patent/EP2195036A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP08725637A 2007-10-05 2008-02-15 COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE Withdrawn EP2195036A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99785607P 2007-10-05 2007-10-05
US99787307P 2007-10-05 2007-10-05
PCT/US2008/002026 WO2009045230A1 (en) 2007-10-05 2008-02-15 Compositions for treatment of tumors by direct administration of a radioisotope

Publications (2)

Publication Number Publication Date
EP2195036A1 EP2195036A1 (en) 2010-06-16
EP2195036A4 true EP2195036A4 (en) 2011-03-09

Family

ID=40526495

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08725637A Withdrawn EP2195036A4 (en) 2007-10-05 2008-02-15 COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE

Country Status (4)

Country Link
EP (1) EP2195036A4 (es)
JP (1) JP2010540627A (es)
CA (1) CA2701537A1 (es)
WO (1) WO2009045230A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008232A2 (en) 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
DOP2010000279A (es) * 2009-09-18 2012-06-15 Sari Asher Llc Composiciones radiofarmaceuticas no-coloidales sin sellar y metodos para el tratamiento de tejido anormal
CN102859608B (zh) * 2010-03-09 2016-08-03 库里昂股份有限公司 使用离子特异性介质的同位素特异性分离和玻璃化
US9714457B2 (en) 2012-03-26 2017-07-25 Kurion, Inc. Submersible filters for use in separating radioactive isotopes from radioactive waste materials
GB2490317A (en) * 2011-04-19 2012-10-31 Dspi Ltd Radioactive solution undergoing in situ precipitation at a tumour site for cancer therapy
WO2013096776A2 (en) * 2011-12-21 2013-06-27 Iso Therapeutics Group Llc Radioactive compositions and methods for their therapeutic use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313273A1 (en) * 1987-10-14 1989-04-26 Australian Nuclear Science And Technology Organisation Macroaggregates for radiation synovectomy
US4849209A (en) * 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
AU2005290229A1 (en) * 2004-09-24 2006-04-06 Biosphere Medical, Inc. Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849209A (en) * 1985-06-07 1989-07-18 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide
EP0313273A1 (en) * 1987-10-14 1989-04-26 Australian Nuclear Science And Technology Organisation Macroaggregates for radiation synovectomy
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JONG D L ET AL: "Effective local control of malignant melanoma by intratumoural injection of a beta-emitting radionuclide", EUROPEAN JOURNAL OF NUCLEAR MEDICINE 2002 DE LNKD- DOI:10.1007/S00259-001-0696-Y, vol. 29, no. 2, 2002, pages 221 - 230, XP002618948, ISSN: 0340-6997 *
MCCREADY V R ET AL: "The potential of intratumoural unsealed radioactive source therapy.", EUROPEAN JOURNAL OF NUCLEAR MEDICINE MAY 2001 LNKD- PUBMED:11383859, vol. 28, no. 5, May 2001 (2001-05-01), pages 567 - 569, XP002618949, ISSN: 0340-6997 *
See also references of WO2009045230A1 *

Also Published As

Publication number Publication date
JP2010540627A (ja) 2010-12-24
EP2195036A1 (en) 2010-06-16
CA2701537A1 (en) 2009-04-09
WO2009045230A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
HK1253355A1 (zh) 含有馬西替坦的治療組合物
EP2211620A4 (en) THERAPEUTIC COMPOUNDS
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
EP2152722A4 (en) COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER
EP2127671A4 (en) THERAPEUTIC AGENT AGAINST CANCER
EP2268285A4 (en) THERAPEUTIC COMPOUNDS
GB0716532D0 (en) Therapeutic compounds
GB0813087D0 (en) Therapeutic compounds
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
EP2164324A4 (en) THERAPEUTIC COMPOUNDS
GB0808835D0 (en) Therapeutic compositions
EP2195036A4 (en) COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE
GB0819958D0 (en) Therapeutic compositions
EP2331092A4 (en) METHOD AND COMPOSITIONS FOR THE ADMINISTRATION OF 3-HALOPYRUVATE AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER
EP2185568A4 (en) THERAPEUTIC COMPOUNDS
EP2407162A4 (en) COMPOSITION FOR ORAL ADMINISTRATION
EP2099303A4 (en) THERAPEUTIC COMPOSITIONS ON TETRAHYDROISOCHINOLINE BASE FOR CANCER THERAPY
GB0702862D0 (en) Therapeutic compounds
EP2197454A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
GB0708188D0 (en) Therapeutic compounds
GB0710144D0 (en) Therapeutic compositions
GB0717571D0 (en) Therapeutic compounds
GB0713865D0 (en) Therapeutic compounds
GB0717569D0 (en) Therapeutic compounds
GB0722401D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GABRIEL INSTITUTE, INC.

Owner name: ISOTHERAPEAUTICS GROUP LLC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110209

17Q First examination report despatched

Effective date: 20120514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150901